MarketCapExport financials
Capricor Therapeutics (CAPR)
The export includes the complete available history of financial statements and ratios. Numbers are provided in full, without million or billion abbreviations, in their original reporting units.
CSV downloads as a ZIP archive with one file for each report and frequency.
Facebook
X
Telegram
Capricor Therapeutics Income Statement 2025-2005 | CAPR
Brief overview of income trends at Capricor Therapeutics
The overview follows changes across a five-year period. Capricor Therapeutics reported revenue of $1 million in 2019 and $22.3 million by 2024. Across the full period, sales moved by +2115.9%; the average annual rate was 85.8%. This pace points to rapid expansion of the business.
The operating result measured by EBITDA moved from −$7.6 million to −$41.1 million, or −444%. EBITDA underperformed the top-line trend. The EBITDA share of revenue changed from −752.4% to −184.7%. The company improved its ability to convert sales into EBITDA.
The final result was −$7.6 million initially and −$40.5 million in the final year. Profitability deteriorated further over the five years.
Over the period, capitalization shifted from 5.7 million dollars to 1.1 billion dollars (+19119.3%). A large part of future progress may already be reflected in the valuation.
Conclusion
Positive developments coexist with areas of weakness. The financial profile benefits from a larger revenue base and an improving EBITDA margin. The weaker side of the profile includes declining net profitability and limited operating profitability. Further direction will depend on top-line growth, operating profitability, and net income.
Annual Income Statement Capricor Therapeutics
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Market Cap |
1.45 B | 1.1 B | 155 M | 109 M | 82.4 M | 102 M | 5.72 M | 15.3 M | 43.8 M | 40.4 M | 42.5 M | 76 M | 138 M | 5.06 M | 19.8 M | 7.79 B | - | - | - | - | - |
Shares |
46.5 M | 35.2 M | 26.8 M | 24.6 M | 23.1 M | 15.6 M | 3.71 M | 2.94 M | 2.32 M | 1.86 M | 1.59 M | 1.17 M | 1.05 M | 84.4 K | 74.7 K | 34.6 M | - | - | - | - | - |
Historical Prices |
31.2 | 31.2 | 5.8 | 4.42 | 3.57 | 6.58 | 1.53 | 5.1 | 20 | 24.4 | 26.7 | 65 | 135 | 60 | 255 | 225 | 360 | 2.6 K | 1.02 K | - | - |
Net Income |
-105 M | -40.5 M | -22.3 M | -29 M | -20 M | -13.7 M | -7.64 M | -15.2 M | 2.43 M | -18.8 M | -12.9 M | -6.22 M | -8.89 M | -1.89 M | -4.88 M | -1.06 M | -149 K | -631 K | -979 K | -1.17 M | 36 |
Revenue |
- | 22.3 M | 25.2 M | 2.55 M | 245 K | 310 K | 1.01 M | 1.67 M | 2.67 M | 4 M | 5.52 M | 4.79 M | 503 K | 196 K | 1.35 M | - | - | - | - | - | - |
Gross Profit |
- | - | - | - | - | 310 | - | - | - | - | 5.52 M | 4.79 M | 503 K | 196 K | 1.35 M | - | - | - | - | - | - |
Operating Income |
-108 M | -42.6 M | -24.1 M | -29.7 M | -20.9 M | -13.7 M | -7.73 M | -15.3 M | -12.9 M | -17 M | -12.6 M | -6.02 M | -6.9 M | -2.1 M | -4.9 M | -6.29 M | - | - | - | - | - |
Interest Expense |
- | - | - | - | - | - | - | - | 399 K | 345 K | 249 K | 201 K | 58.1 K | - | - | 242 K | - | - | - | - | - |
EBITDA |
-106 M | -41.1 M | -23 M | -29.2 M | -20.7 M | -13.5 M | -7.56 M | -15.2 M | -12.7 M | -16.9 M | -12.5 M | -5.98 M | -6.88 M | -2.43 M | -4.89 M | -6.28 M | - | - | - | - | - |
Operating Expenses |
108 M | 64.8 M | 49.3 M | 32.2 M | 21.2 M | 14 M | 8.74 M | 17 M | 15.5 M | 21 M | 18.1 M | 10.8 M | 7.41 M | 2.64 M | 6.25 M | 6.29 M | - | - | - | - | - |
General and Administrative Expenses |
23.7 M | 14.9 M | 12.8 M | 10.4 M | 7.61 M | 5.54 M | 3.6 M | 4.93 M | 4.76 M | 4.93 M | 4.37 M | 3.02 M | 2.21 M | 1.61 M | 2.12 M | 2.21 M | - | - | - | - | - |
Annual performance
Select metrics to display
All numbers in USD currency
Quarterly Income Statement Capricor Therapeutics
| 2026-Q1 | 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Shares |
57.4 M | 45.7 M | 45.7 M | 45.6 M | 45.6 M | 33.1 M | 31.8 M | 31.4 M | 31.1 M | 25.8 M | 25.3 M | 25.2 M | 25.2 M | 24.4 M | 24.3 M | 24.3 M | 24.2 M | 23.1 M | 22.9 M | 22.2 M | 20.6 M | 19.8 M | 15.1 M | 6.88 M | 5.23 M | 3.75 M | 3.46 M | 3.35 M | 3.14 M | 3.06 M | 2.9 M | 26.9 M | 26.3 M | 23.4 M | 22.1 M | 21.4 M | 21.4 M | 18.3 M | 18 M | 16.5 M | 16.3 M | 16.2 M | 16.2 M | 14.9 M | 11.7 M | 11.7 M | 11.7 M | 11.7 M | 11.7 M | 10.4 M | 10.4 M | 10.4 M | 10.4 M | 43.1 M | 43 M | 39.7 M | 39.7 M | 39.7 M | 35.1 M | 39.7 M |
Net Income |
-33.9 M | -24.6 M | -25.9 M | -24.4 M | - | -12.6 M | -11 M | -9.79 M | - | -6.39 M | -7.37 M | -7.77 M | - | -6.37 M | -7.11 M | -7.82 M | - | -3.93 M | -4.75 M | -5.15 M | - | -3.91 M | -3.48 M | -2.08 M | - | -1.61 M | -2.05 M | -2.52 M | - | -4.14 M | -4.12 M | -3.67 M | - | -2.73 M | -3.47 M | -3.67 M | - | -5.33 M | -4.69 M | -4.27 M | - | -2.91 M | -3.12 M | -3.48 M | - | -1.54 M | -1.53 M | -1.21 M | - | -1.55 M | -1.62 M | -8.89 M | - | -1.89 M | -1.89 M | -1.89 M | - | -4.88 M | -4.88 M | -4.88 M |
Revenue |
- | - | - | - | - | 2.26 M | 3.97 M | 4.91 M | - | 6.19 M | 3.92 M | 2.99 M | - | 1.59 M | - | - | - | 245 K | 204 K | 40.8 K | - | 16.9 K | 49.9 K | 186 K | - | 142 K | 410 K | 231 K | - | 219 K | 404 K | 400 K | - | 313 K | 996 K | 881 K | - | 747 K | 1.13 M | 1.22 M | - | 1.31 M | 1.29 M | 1.79 M | - | 1.3 M | 1.04 M | 1.04 M | - | 80.4 K | 190 K | 233 K | - | - | - | 196 K | - | 813 K | 346 K | - |
Operating Income |
-36.8 M | -26.3 M | -27.7 M | -25 M | - | -13 M | -11.6 M | -10.3 M | - | -6.86 M | -7.75 M | -8.18 M | - | -6.48 M | -7.32 M | -7.83 M | - | -4.31 M | -5.08 M | -5.16 M | - | -3.91 M | -3.49 M | -2.11 M | - | -1.63 M | -2.07 M | -2.56 M | - | -4.17 M | -4.16 M | -3.69 M | - | -2.64 M | -3.38 M | -3.57 M | - | -5.24 M | -4.61 M | -4.21 M | - | -2.85 M | -3.06 M | -3.41 M | - | -1.49 M | -1.48 M | -1.19 M | - | -1.49 M | -1.62 M | -1.43 M | - | -576 K | -774 K | -770 K | - | -1.16 M | -880 K | -1.2 M |
Interest Expense |
- | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 108 K | 106 K | 105 K | - | 98.7 K | 76.9 K | 66.1 K | - | 61.7 K | 61.7 K | 61.7 K | - | 60.1 K | 54.7 K | 25.3 K | - | 23.4 K | 6.21 K | 3.71 K | - | - | - | - | - | - | -1.34 K | -168 |
EBITDA |
-36.2 M | -25.8 M | -27.2 M | -24.6 M | - | -12.6 M | -11.2 M | -9.93 M | - | -6.59 M | -7.49 M | -7.95 M | - | -6.34 M | -7.21 M | -7.74 M | - | -4.15 M | -4.98 M | -5.11 M | - | -3.81 M | -3.42 M | -2.07 M | - | -1.5 M | -1.98 M | -2.51 M | - | -4.06 M | -4.09 M | -3.65 M | - | -2.53 M | -3.3 M | -3.53 M | - | -5.15 M | -4.55 M | -4.18 M | - | -2.77 M | -3.01 M | -3.39 M | - | -1.46 M | -1.46 M | -1.18 M | - | -1.47 M | -1.6 M | -1.43 M | - | -572 K | -771 K | -768 K | - | -1.15 M | -876 K | -1.2 M |
Operating Expenses |
36.8 M | 26.3 M | 27.7 M | 25 M | - | 15.3 M | 15.6 M | 15.2 M | - | 13.1 M | 11.7 M | 11.2 M | - | 8.07 M | 7.32 M | 7.83 M | - | 4.31 M | 5.29 M | 5.2 M | - | 3.93 M | 3.54 M | 2.29 M | - | 1.77 M | 2.48 M | 2.79 M | - | 4.39 M | 4.57 M | 4.09 M | - | 2.95 M | 4.38 M | 4.45 M | - | 5.99 M | 5.74 M | 5.43 M | - | 4.17 M | 4.35 M | 5.2 M | - | 2.79 M | 2.52 M | 2.23 M | - | 1.57 M | 1.8 M | 1.67 M | - | 576 K | 774 K | 965 K | - | 1.97 M | 1.23 M | 1.2 M |
General and Administrative Expenses |
9.4 M | 5.92 M | 5.67 M | 6.07 M | - | 3.46 M | 3.06 M | 4.07 M | - | 3.02 M | 2.85 M | 3.51 M | - | 2.56 M | 2.36 M | 2.72 M | - | 1.8 M | 1.79 M | 1.91 M | - | 1.3 M | 1.61 M | 1.14 M | - | 912 K | 832 K | 976 K | - | 1.26 M | 1.18 M | 1.39 M | - | 1.09 M | 1.25 M | 1.19 M | - | 1.26 M | 1.43 M | 1.08 M | - | 973 K | 926 K | 1.4 M | - | 820 K | 666 K | 852 K | - | 564 K | 493 K | 474 K | - | 397 K | 442 K | 500 K | - | 499 K | 523 K | 575 K |
Quarterly performance
Select metrics to display
All numbers in USD currency
The income statement is one of the three key financial reports of a company Capricor Therapeutics (alongside the balance sheet and the cash flow statement). It shows how the company makes money and what its expenses are:
- How much revenue the company earned
- How much it spent on production, personnel, marketing, taxes, etc.
- What profit remained in the end
Analyzing the income statement helps an investor understand whether the business generates stable and growing profits, how effectively the company controls its expenses, and whether it is capable of generating income in the future. Additionally, this analysis shows how the company copes with crises and economic cycles, and allows assessing the potential for stock price growth and dividend payments.
Features- The income statement may include both recurring and one-time items (for example, profit from the sale of assets). It is necessary to separate core metrics from one-off events for accurate analysis.
- Companies often publish interim reports (e.g., quarterly), which allows for more timely tracking of trends.
- A combined analysis of the income statement with the balance sheet and cash flow statement provides a comprehensive view of the company’s financial health.
Russia
USA
Canada
Niderland
Israel
Spain
Germany
Australia
Britain
